HPV (CERVARIX) VACCINE

VACCINE USAGE: CERVARIX is a vaccine indicated for the prevention of the following diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18: cervical cancer, cervical intraepithelial neoplasia (CIN) Grade 2 or worse and adenocarcinoma in situ, and cervical intraepithelial neoplasia (CIN) Grade 1.

CERVARIX is approved for use in females 9 through 25 years of age. Limitations of Use and Effectiveness.

CERVARIX does not provide protection against disease due to all HPV types.

CERVARIX has not been demonstrated to provide protection against disease from vaccine and non-vaccine HPV types to which a woman has previously been exposed through sexual activity.

THIS VACCINE WAS DISCONTINUED IN 2016

VACCINE DOSAGE: three doses (0.5-mL each) by intramuscular injection according to the following schedule: 0, 1, and 6 months.

VACCINE INGEDIENTS: vitamins, amino acids, lipids, mineral salts, aluminum hydroxide, sodium dihydrogen phosphate dihydrate, insect cell and viral protein, 3-0-desacyl-4′ Monophosphoryl lipid.

ADVERSE VACCINE REACTIONS: extreme pain, headache, nasopharyngitis, influenza, dizziness, upper respiratory infection, dysmenorrhea, chlamydia infection, pharyngitis, injection site bruising, vaginal infection, back pain, UTI, arthritis, celiac disease, dermatomyositis, diabetes, hyperthyroidism, hypothyroidism, inflammatory bowel disease, psoriasis, death, allergies, vitiligo, seizures.